DECIBEL CANNABIS CO INC (DB.CA) Stock Fundamental Analysis
TSX-V:DB - TSX Venture Exchange - CA2434371001 - Common Stock - Currency: CAD
DB gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 35 industry peers in the Pharmaceuticals industry. There are concerns on the financial health of DB while its profitability can be described as average. DB is not priced too expensively while it is growing strongly. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
In the past year DB has reported negative net income.
In the past year DB had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: DB reported negative net income in multiple years.
In multiple years DB reported negative operating cash flow during the last 5 years.
1.2 Ratios
The Return On Assets of DB (7.45%) is better than 94.29% of its industry peers.
DB has a better Return On Equity (17.30%) than 97.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.45% | ||
| ROE | 17.3% | ||
| ROIC | N/A |
ROA(3y)0.61%
ROA(5y)-1.43%
ROE(3y)0.45%
ROE(5y)-4.55%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 11.74%, DB belongs to the top of the industry, outperforming 88.57% of the companies in the same industry.
In the last couple of years the Profit Margin of DB has grown nicely.
DB's Gross Margin of 28.07% is on the low side compared to the rest of the industry. DB is outperformed by 60.00% of its industry peers.
DB's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 11.74% | ||
| GM | 28.07% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y45.46%
PM growth 5YN/A
GM growth 3Y72.19%
GM growth 5Y-2.05%
2. Health
2.1 Basic Checks
DB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, DB has more shares outstanding
Compared to 5 years ago, DB has more shares outstanding
The debt/assets ratio for DB has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 0.92, we must say that DB is in the distress zone and has some risk of bankruptcy.
With a decent Altman-Z score value of 0.92, DB is doing good in the industry, outperforming 77.14% of the companies in the same industry.
The Debt to FCF ratio of DB is 34.70, which is on the high side as it means it would take DB, 34.70 years of fcf income to pay off all of its debts.
DB's Debt to FCF ratio of 34.70 is in line compared to the rest of the industry. DB outperforms 57.14% of its industry peers.
A Debt/Equity ratio of 0.58 indicates that DB is somewhat dependend on debt financing.
DB has a Debt to Equity ratio (0.58) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.58 | ||
| Debt/FCF | 34.7 | ||
| Altman-Z | 0.92 |
ROIC/WACCN/A
WACC8.25%
2.3 Liquidity
DB has a Current Ratio of 1.33. This is a normal value and indicates that DB is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of DB (1.33) is comparable to the rest of the industry.
A Quick Ratio of 0.43 indicates that DB may have some problems paying its short term obligations.
DB's Quick ratio of 0.43 is on the low side compared to the rest of the industry. DB is outperformed by 77.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.33 | ||
| Quick Ratio | 0.43 |
3. Growth
3.1 Past
DB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 1050.00%, which is quite impressive.
Measured over the past years, DB shows a very strong growth in Earnings Per Share. The EPS has been growing by 90.70% on average per year.
DB shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -15.44%.
The Revenue has been growing by 71.51% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)1050%
EPS 3Y90.7%
EPS 5YN/A
EPS Q2Q%70%
Revenue 1Y (TTM)-15.44%
Revenue growth 3Y20.83%
Revenue growth 5Y71.51%
Sales Q2Q%1.36%
3.2 Future
DB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 133.50% yearly.
The Revenue is expected to grow by 9.64% on average over the next years. This is quite good.
EPS Next Y372.03%
EPS Next 2Y124.94%
EPS Next 3Y133.5%
EPS Next 5YN/A
Revenue Next Year22.66%
Revenue Next 2Y22.65%
Revenue Next 3Y17.87%
Revenue Next 5Y9.64%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Forward Earnings ratio is 3.43, which indicates a rather cheap valuation of DB.
Compared to the rest of the industry, the Price/Forward Earnings ratio of DB indicates a rather cheap valuation: DB is cheaper than 97.14% of the companies listed in the same industry.
DB's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 34.04.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 3.43 |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, DB is valued a bit cheaper than 62.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 44.6 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
DB's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
DB's earnings are expected to grow with 133.50% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y124.94%
EPS Next 3Y133.5%
5. Dividend
5.1 Amount
No dividends for DB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX-V:DB (8/8/2025, 7:00:00 PM)
0.105
+0.01 (+10.53%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners4.97%
Ins Owner ChangeN/A
Market Cap60.57M
Analysts82.22
Price Target0.26 (147.62%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-8.23%
Min Revenue beat(2)-12.15%
Max Revenue beat(2)-4.31%
Revenue beat(4)1
Avg Revenue beat(4)-5.23%
Min Revenue beat(4)-12.15%
Max Revenue beat(4)0.44%
Revenue beat(8)2
Avg Revenue beat(8)-2.91%
Revenue beat(12)4
Avg Revenue beat(12)-0.89%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-11.75%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-9.23%
Revenue NY rev (3m)-8.95%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 3.43 | ||
| P/S | 0.65 | ||
| P/FCF | 44.6 | ||
| P/OCF | 25.62 | ||
| P/B | 0.96 | ||
| P/tB | 0.98 | ||
| EV/EBITDA | N/A |
EPS(TTM)0
EYN/A
EPS(NY)0.03
Fwd EY29.14%
FCF(TTM)0
FCFY2.24%
OCF(TTM)0
OCFY3.9%
SpS0.16
BVpS0.11
TBVpS0.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.45% | ||
| ROE | 17.3% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 11.74% | ||
| GM | 28.07% | ||
| FCFM | 1.46% |
ROA(3y)0.61%
ROA(5y)-1.43%
ROE(3y)0.45%
ROE(5y)-4.55%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y45.46%
PM growth 5YN/A
GM growth 3Y72.19%
GM growth 5Y-2.05%
F-Score5
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.58 | ||
| Debt/FCF | 34.7 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 18.51% | ||
| Cap/Sales | 1.08% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | 12.46% | ||
| Current Ratio | 1.33 | ||
| Quick Ratio | 0.43 | ||
| Altman-Z | 0.92 |
F-Score5
WACC8.25%
ROIC/WACCN/A
Cap/Depr(3y)70.46%
Cap/Depr(5y)95.47%
Cap/Sales(3y)2.65%
Cap/Sales(5y)5.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1050%
EPS 3Y90.7%
EPS 5YN/A
EPS Q2Q%70%
EPS Next Y372.03%
EPS Next 2Y124.94%
EPS Next 3Y133.5%
EPS Next 5YN/A
Revenue 1Y (TTM)-15.44%
Revenue growth 3Y20.83%
Revenue growth 5Y71.51%
Sales Q2Q%1.36%
Revenue Next Year22.66%
Revenue Next 2Y22.65%
Revenue Next 3Y17.87%
Revenue Next 5Y9.64%
EBIT growth 1Y-316.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year315.52%
EBIT Next 3Y73.13%
EBIT Next 5Y45.35%
FCF growth 1Y-70.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-68.85%
OCF growth 3YN/A
OCF growth 5YN/A